propranolol has been researched along with Cancer of Prostate in 13 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incubation of prostate cancer cells with 10-fold molar excess of propranolol for 30 min inhibited all downstream pathways activated by epinephrine." | 1.91 | Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells. ( Abdulraqeb Ali, A; Alaiya, A; Alaskar, A; Hassan, S; Kulik, G; Miller, L; Shinwari, Z; von Holzen, U, 2023) |
| "Propranolol treatment elevated the activity of caspase-3 and expression of bax, Wee1, GADD153 and apoptosis-inducing factor, but decreased bcl-2 which is an antiapoptotic protein." | 1.72 | Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways. ( Özler, S; Pazarci, P, 2022) |
| "The propranolol +2DG treatment efficiently prevents prostate cancer cell proliferation, induces cell apoptosis, alters mitochondrial morphology, inhibits mitochondrial bioenergetics and aggravates ER stress in vitro and also suppresses tumor growth in vivo." | 1.48 | Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. ( Brohée, L; Castronovo, V; Colige, AC; Deroanne, CF; Nusgens, B; Peulen, O; Thiry, M, 2018) |
| "The proliferation of prostate and breast cancer cells, but not of non-tumorigenic cells, was repressed upon lipin-1 knock-down." | 1.42 | Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. ( Arnould, T; Brohée, L; Colige, AC; Demine, S; Deroanne, CF; Willems, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Wlodarczyk, N | 1 |
| Le Broc-Ryckewaert, D | 1 |
| Gilleron, P | 1 |
| Lemoine, A | 1 |
| Farce, A | 1 |
| Chavatte, P | 1 |
| Dubois, J | 1 |
| Pommery, N | 1 |
| Hénichart, JP | 1 |
| Furman, C | 1 |
| Millet, R | 1 |
| Bassetto, M | 1 |
| Ferla, S | 1 |
| Pertusati, F | 1 |
| Kandil, S | 1 |
| Westwell, AD | 1 |
| Brancale, A | 1 |
| McGuigan, C | 1 |
| Xiang, Q | 2 |
| Wang, C | 2 |
| Wu, T | 2 |
| Zhang, C | 2 |
| Hu, Q | 2 |
| Luo, G | 2 |
| Hu, J | 2 |
| Zhuang, X | 2 |
| Zou, L | 1 |
| Shen, H | 1 |
| Wu, X | 1 |
| Zhang, Y | 2 |
| Kong, X | 1 |
| Liu, J | 2 |
| Xu, Y | 2 |
| Xu, H | 1 |
| Zhang, M | 1 |
| Wu, S | 1 |
| Xu, J | 1 |
| Özler, S | 1 |
| Pazarci, P | 1 |
| Alaskar, A | 1 |
| Abdulraqeb Ali, A | 1 |
| Hassan, S | 1 |
| Shinwari, Z | 1 |
| Alaiya, A | 1 |
| von Holzen, U | 1 |
| Miller, L | 1 |
| Kulik, G | 1 |
| Brohée, L | 2 |
| Peulen, O | 1 |
| Nusgens, B | 1 |
| Castronovo, V | 1 |
| Thiry, M | 1 |
| Colige, AC | 2 |
| Deroanne, CF | 2 |
| Demine, S | 1 |
| Willems, J | 1 |
| Arnould, T | 1 |
| Barbieri, A | 1 |
| Bimonte, S | 1 |
| Palma, G | 1 |
| Luciano, A | 1 |
| Rea, D | 1 |
| Giudice, A | 1 |
| Scognamiglio, G | 1 |
| La Mantia, E | 1 |
| Franco, R | 1 |
| Perdonà, S | 1 |
| De Cobelli, O | 1 |
| Ferro, M | 1 |
| Zappavigna, S | 1 |
| Stiuso, P | 1 |
| Caraglia, M | 1 |
| Arra, C | 1 |
| Friedman, GD | 1 |
| Udaltsova, N | 1 |
| Habel, LA | 1 |
| Strell, C | 1 |
| Niggemann, B | 1 |
| Voss, MJ | 1 |
| Powe, DG | 1 |
| Zänker, KS | 1 |
| Entschladen, F | 1 |
| De Giorgi, V | 1 |
| Gandini, S | 1 |
| Grazzini, M | 1 |
| Benemei, S | 1 |
| Marchionni, N | 1 |
| Geppetti, P | 1 |
| Caine, M | 1 |
| Mazouz, B | 1 |
| Rossini, BM | 1 |
13 other studies available for propranolol and Cancer of Prostate
| Article | Year |
|---|---|
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
Topics: Androgen Antagonists; Azepines; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screeni | 2011 |
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Che | 2016 |
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; CREB-Binding Protein; Drug Design; H | 2022 |
Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carrier Proteins; Cell Line, Tumor; DNA-Binding Prote | 2022 |
Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Female; Humans; Male; Mitogen-Activated Pr | 2022 |
Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
Topics: Animals; Epinephrine; Humans; Male; Mice; Phosphorylation; Propranolol; Prostate; Prostatic Neoplasm | 2023 |
Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression.
Topics: Animals; Autophagy; Carbohydrate Metabolism; Cell Line, Tumor; Disease Models, Animal; Disease Progr | 2018 |
Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; B | 2015 |
The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Gene Expression Regulati | 2015 |
Norepinephrine antagonists and cancer risk.
Topics: Atenolol; Breast Neoplasms; Clonidine; Colonic Neoplasms; Female; Humans; Lung Neoplasms; Male; Meto | 2011 |
Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release.
Topics: Adrenergic beta-Antagonists; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL1; End | 2012 |
[β-blockers: a new and emerging treatment for melanoma].
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Evidenc | 2012 |
The effect of nicergoline on the lower urinary tract muscle.
Topics: Adenoma; Adrenergic alpha-Antagonists; Animals; Dogs; Dose-Response Relationship, Drug; Ergolines; F | 1984 |